An FDA committee on Friday approved a third Pfizer dose six months after full vaccination for people 65 and older or at high risk of severe COVID-19.
FDA committee says Pfizer-BioNTech boosters should be targeted, citing lack of data for people under 65. Latest COVID-19 updates
